5 trends shaping rare disease drug development
Amid criticism of rising prescription drug costs, the 1983 Orphan Drug Act, which granted drugmakers of a rare disease drug seven years of marketing exclusivity, has become a hot topic.
Increased investment in rare diseases mixed with high prices for orphan drugs is making some wonder if reform is needed. With sales of orphan drugs expected to grow, BioPharma Dive pinpoints the 5 trends shaping rare disease drug development:
1. Soaring industry interest
2. Rising sales
3. Pushback on prices
4. Not just biotechs, big pharma too
5. Medical advances
